Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange 02:36:12 2024-03-28 am EDT 5-day change 1st Jan Change
4,203 JPY -2.12% Intraday chart for Takeda Pharmaceutical Company Limited -4.06% +3.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder MT
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura CI
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba MT
Takeda Pharmaceutical Receives FDA Approval to Expand Iclusig's Indication in Blood Cancer Sub-Type MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics MT
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® in Adult Patients with Newly Diagnosed Ph+ ALL CI
Takeda Pharmaceutical Says Mezagitamab Phase 2 Trial Shows 'Positive' Results in Primary Immune Thrombocytopenia Patients MT
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia CI
Toyota becomes Asia's most shorted large-cap stock - Hazeltree RE
India's Serum looks beyond COVID with new vaccines for malaria, dengue RE
EARNINGS: Hutchmed revenue surges, Craven House's loss widens AN
Takeda Pharmaceutical Teams Up With Biological E. to Boost Production of Dengue Vaccine MT
HEDGEFLOW - Japan enthusiasm driving inflows to US-listed Asian equities, Morgan Stanley says RE
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production RE
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas CI
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited CI
Sector Update: Health Care Stocks Mixed Pre-Bell Monday MT
Takeda Pharmaceutical Says US FDA Approves Eohilia as Eosinophilic Esophagitis Treatment MT
US FDA approves Takeda's therapy for allergic inflammation in esophagus RE
FDA Approves Takeda's EOHILIA (budesonide Oral Suspension) CI
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 CI
Takeda Pharmaceutical Names Milano Furuta as Chief Financial Officer MT
Takeda Pharmaceutical's Attributable Profit Down 48.6% in Fiscal Nine Months Higher Expenses, Wider Impairment Losses MT
Takeda Pharmaceutical's Q3 Core Earnings Decline, Revenue Increases MT
Chart Takeda Pharmaceutical Company Limited
More charts
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,388 JPY
Average target price
4,790 JPY
Spread / Average Target
+9.16%
Consensus
  1. Stock
  2. Equities
  3. Stock Takeda Pharmaceutical Company Limited - Japan Exchange
  4. News Takeda Pharmaceutical Company Limited
  5. Takeda Pharmaceutical : Provides Updates on Moderna, Novavax COVID-19 Vaccine Candidates in Japan